These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 21349032)

  • 1. Promoting evidence-based development and use of traditional Chinese medicine injections.
    Ren D
    J Evid Based Med; 2010 Feb; 3(1):2-3. PubMed ID: 21349032
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical orientation of post-marketing Chinese patent drugs: an evidence-based practice].
    Shang HC; Zhang BL; Li YP
    Zhong Xi Yi Jie He Xue Bao; 2008 Sep; 6(9):887-90. PubMed ID: 18782528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Process and key points of clinical literature evaluation of post-marketing traditional Chinese medicine].
    Liu H; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2848-50. PubMed ID: 22292382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Exploration of how to formulate guidelines on post-marketing traditional Chinese medicine surveillance].
    Zhang W; Xie YM; Yu WY
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2943-8. PubMed ID: 24471309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. To establish a body of evidence on safety for postmarketing Chinese medicine: A new research paradigm.
    Liao X; Xie YM; Robinson N; Wang YY
    Chin J Integr Med; 2017 Mar; 23(3):226-232. PubMed ID: 27900605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Designs and thoughts of real world integrated data warehouse from HIS on re-evaluation of post-maketing traditional Chinese medicine].
    Zhuang Y; Xie B; Weng S; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2880-2. PubMed ID: 22292391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Principles of traditional Chinese medicine].
    Meng A
    Wien Med Wochenschr; 2000; 150(13-14):310-6. PubMed ID: 11075432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Post-marketing re-evaluation about usage and dosage of Chinese medicine based on human population pharmacokinetics].
    Jiang J; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2811-2. PubMed ID: 22292372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A discussion of key issues on postmarketing reevaluation of Chinese medicine].
    Xie Y; Tian F
    Zhongguo Zhong Yao Za Zhi; 2010 Jun; 35(11):1494-7. PubMed ID: 20822029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Application of nested case-control study on safe evaluation of post-marketing traditional Chinese medicine injection].
    Xiao Y; Zhao Y; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2796-8. PubMed ID: 22292368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical orientation and thought on several problems in post-marketed reassessment of traditional Chinese medicine].
    Wang X; Su X; Yu J; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2893-7. PubMed ID: 22292394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Brief introduction of the construction of legal system of traditional Chinese medicine in modern China].
    Li Z; Lu ZL
    Zhonghua Yi Shi Za Zhi; 2007 Oct; 37(4):218-21. PubMed ID: 19127846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse drug reactions and adverse events of 33 varieties of traditional Chinese medicine injections on National Essential medicines List (2004 edition) of China: an overview on published literatures.
    Wang L; Yuan Q; Marshall G; Cui X; Cheng L; Li Y; Shang H; Zhang B; Li Y
    J Evid Based Med; 2010 May; 3(2):95-104. PubMed ID: 21349051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacovigilance in Traditional Chinese Medicine safety surveillance.
    Wang H; Ye X; Gao Q; Wu C; Qian Y; Luo B; Sun Y; He J
    Pharmacoepidemiol Drug Saf; 2009 May; 18(5):357-61. PubMed ID: 19253921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Application of regular expression in extracting key information from Chinese medicine literatures about re-evaluation of post-marketing surveillance].
    Wang Z; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2888-90. PubMed ID: 22292393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [To explore evidence evaluation for harm: establishing the body of evidence for harm for postmarketing traditional Chinese medicine].
    Liao X; Xie YM; Wang YY; Nicola R
    Zhongguo Zhong Yao Za Zhi; 2015 Dec; 40(24):4723-7. PubMed ID: 27245012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three therapeutic tendencies for secondary prevention of myocardial infarction and possible role of Chinese traditional patent medicine: viewpoint of evidence-based medicine.
    Shang H; Chen J; Zhang J; Xiang Y; Cao H; Ren M; Wang H; Xu H; Li J; Liu D; Hu J; Wu C; Jing L; Zhang B
    J Evid Based Med; 2009 May; 2(2):84-91. PubMed ID: 21348994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precise reporting of traditional Chinese medicine interventions in randomized controlled trials.
    Bian ZX; Moher D; Li YP; Wu TX; Dagenais S; Cheng CW; Li J; Li TQ
    Zhong Xi Yi Jie He Xue Bao; 2008 Jul; 6(7):661-7. PubMed ID: 18601844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing contribution of China in modern biomedical research. Statistical data from ISI Web of Knowledge.
    Makris GC; Spanos A; Rafailidis PI; Falagas ME
    Med Sci Monit; 2009 Dec; 15(12):SR15-21. PubMed ID: 19946247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development trend of traditional Chinese medicine resources].
    Huang L; Peng H; Xiao P
    Zhongguo Zhong Yao Za Zhi; 2011 Jan; 36(1):1-4. PubMed ID: 21473142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.